Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07871747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)

Study acronym: (MICRO-CART)
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Chimeric Antigen Receptor T-Cell (CAR-T) therapy has transformed the management of large B-cell lymphoma, and multiple myeloma by achieving remarkable responses, yet inconsistent durability and severe toxicities remain major challenges. To bridge this gap, this Phase 1 trial evaluates the safety and tolerability of a cGMP-compliant oral Live Biotherapeutic Product (LBP) consortium, selected for its capacity to produce butyrate, as an adjunct to standard Chimeric Antigen Receptor T-Cell CAR-T therapy, aiming to restore microbiome function, and potentially improve clinical outcomes.
Trial Details
NCT Number NCT07871747
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Lymphoma, B-Cell, Multiple Myeloma
Related terms Lymphoma, B-Cell, Multiple Myeloma
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov